Although stroke is a major cause of death and permanent disability, its acute treatment largely remains an evidencefree zone. Currently, there are only two therapies of proven benefi t. First, two randomised controlled trials showed moderate effects from thrombolysis with recombinant tissue-type plasminogen activator administered during the fi rst 3.0 or 4.5 h after stroke, respectively. Second, decompressive surgery has been shown to reduce mortality after space-occupying stroke. Unfortunately, these therapies are applicable for a minority of stroke patients only, and there is no evidenced-based treatment for haemorrhagic stroke at all. Thus, almost all therapies and interventions performed daily in our stroke units lack solid scientifi c evidence, underscoring the need for new therapies.
An impressive body of evidence demonstrates that fever is associated with a worse prognosis in ischaemic and haemorrhagic stroke, with infection being the main cause of fever. The association between infection itself and outcome is less clear. As with other severe illnesses, infections are common after stroke. Moreover, experimental data have led to the hypothesis that a specifi c stroke-induced immunodefi ciency may predispose for infections. Given these considerations, preventive antibiotic therapy appears to be a promising treatment option in acute stroke.
Van de Beek and colleagues summarise four studies on preventive antibiotics in acute stroke. They conclude that although preventive antibiotics may reduce infection, they do not reduce mortality. There are several points of criticism regarding this work. First, the authors neglect an older study published in a non-English-language journal. 1 At the same time, the inclusion of the study by Lampl and colleagues 2 makes little sense because in this study minocycline, a secondgeneration tetracycline derivative that is not a fi rst-line or second-line antibiotic for most infections commonly present after stroke, was used not to prevent infections but to analyse its potential neuroprotective properties. Accordingly, this study did not monitor infections.
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A glimpse at table 1 of van de Beek and colleagues' article also reveals that the four studies analysed differed greatly in their inclusion criteria and primary outcomes. Whereas Chamorro and colleagues 3 included patients with ischaemic and haemorrhagic stroke, the other studies analysed ischaemic stroke only. Chamorro and colleagues included patients with mild-severe stroke, Harms and colleagues 4 included patients with moderate-severe defi cits, and Schwarz and colleagues 5 included only severely ill, bedridden patients. In none of these studies was mortality a central outcome. The Schwarz article even excluded patients with an estimated life expectancy of <6 months. Thus a meta-analysis of these trials focusing on mortality is of rather limited relevance.
Why have studies on preventive antibiotic treatment not been unequivocally positive? This question is particularly pertinent for the largest trial, by Chamorro and colleagues, which was interrupted prematurely after an interim analysis revealed that the rate of infection was even higher in the active treatment group. One possible explanation is the choice of antibiotic drug, which might have been largely driven by the industrial sponsor's interest to market not the most suitable but the newest and most expensive drug. This holds particularly true for the fl uoroquinolones employed in two of the three prevention trials, owing to their potential neurotoxic and arrhythmogenic properties. Recently, the European Medicines Agency restricted the use of moxifl oxacin as fi rst-line antibiotic drug on the basis of infrequent but life-threatening hepatic complications, rendering this drug scarcely suitable for prevention purposes.
In light of the evidence from either negative or small pilot trials, a large clinical trial is clearly warranted. If proven benefi cial, preventive antibiotic treatment could be broadly applied in a large group of patients. Considering the drawbacks of the previous studies, I would advocate simple inclusion criteria that can be readily transferred to everyday practice, along with reliable clinical outcome parameters. The antibiotic drug selected should have no potential neurotoxic or arrhythmogenic side effects, be widely available, and, if possible, be affordable. The study should primarily include severely ill patients, as this group shows the highest risk for infection.
